A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma.

Trial Profile

A Phase II Study to Investigate the Efficacy of RAD001 (Afinitor, Everolimus) in Patients With Irresectable Recurrent or Metastatic Differentiated, Undifferentiated (Anaplastic) and Medullary Thyroid Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms THYRRAD
  • Most Recent Events

    • 01 Nov 2016 Results assessing the impact of hematocrit on pharmacokinetics and pharmacodynamics of everolimus in cancer patients (n=73) from THYRRAD and INPRES trials using semi-physiological pharmacokinetic model, published in the Clinical Pharmacokinetics Journal.
    • 11 Oct 2016 Results assessing effect of old age on pharmacokinetics of Everolimus in cancer patients (n=75) from THYRRAD and INPRES trials presented at the 41st European Society for Medical Oncology Congress
    • 14 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top